Company news

Beijing Hotgen Biotech Co. Ltd. Class A (SSE:688068) news

Beijing Hotgen Biotech Co. Ltd. Class A news releases on 6ix. Latest, Sep 19, 2026: "BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Convening the 2026…

Beijing Hotgen Biotech Co. Ltd. Class A (SSE:688068) news

Press releases & updates

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase I/IIa Clinical Trial of Subsidiary's Innovative Drug SGT003

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Change of Registered Capital, Amendment to the Articles of Association and Filing of Industrial and Commercial Registration Changes

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Implementation Results of Share Repurchase and Share Changes

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Adjustment of Core Technical Personnel

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Obtaining "Drug Clinical Trial Approval" for New Indication of Subsidiary's Innovative Drug SGC001 Injection

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Progress in Repurchasing Shares

Announcement on Voluntary Disclosure of Obtaining the "Drug Clinical Trial Approval Notice" for Subsidiary’s Innovative Drug SGT003 Injection

Announcement on Progress in Repurchasing Shares

Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Restrictions Concerning Share Repurchase

Announcement on Initial Share Repurchase by the Company via Call Auction

Announcement on Early Termination of the Repurchased Shares Sale Plan and the Results of the Sale of Repurchased Shares

Announcement on Serious Abnormal Fluctuations in Stock Trading

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Capital Increase of Joint Stock Company and Related Party Transactions

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes

Announcement on Canceling Some Restricted Stocks Granted and Not Yet Vested

Announcement on Voluntary Disclosure of Obtaining the "Acceptance Notice" for Clinical Trial Application for Subsidiary’s Innovative Drug SGT003 Injection

Announcement on Progress in Disposal of Repurchased Shares

Announcement on Initial Sale of Repurchased Shares Through Call Auction

Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary

Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company

Announcement on Preliminary Earnings Estimate for 2025

Earnings Preannouncement for 2025

Announcement on Plan to Sell Part of Repurchased Shares through Call Auction Transactions

Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025

Announcement on Voluntary Disclosure of Recent Qualifications Obtained by the Joint-stock Company of the Company

Announcement on Joint Investment in Yaojing Gene with a Related Party and Related Party Transaction

Voluntary Disclosure Announcement on Designation as a National-Level "Little Giant" Enterprise (Specialized, Sophisticated, Distinctive, and Innovative)

Announcement on Voluntary Disclosure of Progress in the Share Repurchase through Call Auction

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Result of Shareholding Reduction by Controlling Shareholder

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025

Announcement on Proposal of Canceling the 4th Extraordinary General Meeting in 2025

Announcement on Increasing the Estimated Amount for Daily Related Party Transactions in 2025

Announcement on Voluntary Disclosure of Positive Preliminary Results of the Phase Ib Clinical Study of the Innovative Drug SGC001 of the Joint-stock Company

Announcement on Change in Accounting Estimate

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on Voluntary Disclosure of Recent Qualifications Obtained by the Company and Its Subsidiary

2025 Semi-annual Report

Announcement on Voluntary Disclosure of the Progress in Phase I Clinical Trial for Innovative Drug SGC001 of the Joint-Stock Company

Announcement on Shareholding Reduction Plan for Controlling Shareholders

Announcement on Result of Shareholding Reduction by Shareholders with Over 5% Shares

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Share Reduction Plan for Shareholders with Over 5% Shares

Announcement on Reply to Letter of Regulatory Inquiry on Information Disclosure of 2024 Annual Report

Announcement on Term Change and Election of Board of Directors